NCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
Hunan Province Tumor Hospital
Boehringer Ingelheim
Shanghai JMT-Bio Inc.
National Cancer Institute, Egypt
The Second Affiliated Hospital of Dalian Medical University
Milton S. Hershey Medical Center
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.